New findings highlighted in recent interventional psychiatry research suggest that an experimental psychedelic compound called 25C-NBF may offer a different path forward.
The study, published in Molecular Psychiatry, explored how the synthetic psychedelic compound affected brain structure, depressive behaviors, sensory processing, and addiction-related responses in rodents. Researchers reported that the compound produced rapid antidepressant-like effects while avoiding several issues commonly associated with recreational psychedelics.
Why Current Depression Treatments Still Leave Major Gaps
Major depressive disorder affects millions of people worldwide, yet many available medications still require weeks before meaningful symptom improvement appears. For individuals experiencing severe depression, suicidal thinking, or treatment resistance, those delays can create substantial clinical risks.
Scientists have increasingly focused on psychedelic compounds because many appear capable of rapidly reshaping neural connections in the brain. These substances, often referred to as psychoplastogens, may help restore communication between neurons that becomes disrupted during chronic stress and depression.
However, enthusiasm surrounding psychedelic therapies has also been tempered by concerns involving hallucinations, addiction potential, cardiovascular safety, and unpredictable sensory experiences. Some synthetic phenethylamine psychedelics have demonstrated antidepressant potential, but they also carry elevated risks for abuse and harmful side effects.
How 25C-NBF Antidepressant Effects Stood Apart In Laboratory Testing
The research team, led by scientists from the University of Barcelona and collaborating institutions, investigated a modified class of psychedelic compounds known as NBF analogs. Their goal was to determine whether subtle chemical changes could preserve therapeutic effects while reducing unwanted risks.
Laboratory experiments first examined how the compounds interacted with serotonin receptors, particularly the 5-HT2A receptor closely tied to psychedelic activity. The compounds strongly activated this receptor while showing minimal interaction with the 5-HT2B receptor, which has previously been associated with heart valve complications in long-term drug exposure.
Researchers also found that the compounds activated serotonin signaling pathways in a more balanced manner that resembled natural serotonin activity. This observation raised the possibility that the drugs might influence mood and neural plasticity without producing overwhelming sensory effects.
Animal testing provided additional insight. Mice exposed to the compounds displayed only moderate head-twitch responses, a standard experimental marker associated with hallucinogenic potential. Importantly, the animals did not demonstrate signs of sensory overload or impaired movement. Their exploratory behavior remained largely normal throughout testing.
The Brain Plasticity Findings Driving Interest In 25C-NBF Antidepressant Effects
One of the most significant findings involved the drug’s impact on neuronal growth and connectivity.
After exposure to 25C-NBF, mouse neurons rapidly developed new dendritic branches and expanded cellular extensions linked to communication between brain cells. Researchers also observed increased production of brain-derived neurotrophic factor, or BDNF, a protein strongly associated with neuronal survival and plasticity.
When the compound was administered to live mice, investigators identified increased dendritic spine density in both the prefrontal cortex and hippocampus. These brain regions are heavily involved in emotional regulation, cognition, and memory formation, and they are often negatively affected in depression-related disorders.
The behavioral results added another layer of significance. Rodents exposed to stress models showed measurable improvements after receiving only a single dose of 25C-NBF. In mobility-based behavioral testing, treated animals demonstrated greater effort and persistence compared to untreated stressed mice. These effects reportedly lasted up to one week after administration.
In another experiment examining reward responsiveness, stressed mice regained interest in sugar water shortly after treatment, suggesting improvements in anhedonia-like symptoms commonly associated with depression.
Why Addiction Researchers Are Paying Attention
Another major focus of the study involved abuse liability.
The animals did not appear to find the compound rewarding in conditioned preference experiments. Rats previously trained to self-administer methamphetamine also stopped seeking the drug when it was replaced with an NBF compound. Brain analysis further showed no major dopamine surge within the nucleus accumbens, a region heavily involved in addiction and reinforcement behaviors.
These findings distinguish 25C-NBF from several stimulant or psychedelic compounds that produce rapid dopamine-driven reward signaling.
What Comes Next For Psychedelic Drug Development
Although the results remain preliminary and limited to male rodents, the study adds to growing evidence that future psychedelic medicines may not need to produce intense hallucinations or carry substantial addiction risks to generate antidepressant effects.
Researchers plan to further investigate dosing strategies, cellular signaling pathways, and whether therapeutic benefits can be separated entirely from hallucinogenic experiences. If those goals are achieved, compounds like 25C-NBF could eventually help reshape how clinicians approach rapid psychiatric intervention.
Citations
- Nadal-Gratacós N, Puigseslloses P, Guzman L, et al. The psychedelic phenethylamine 25C-NBF, a selective 5-HT2A agonist, shows psychoplastogenic properties and rapid antidepressant effects in male rodents. Molecular Psychiatry. 2026;31:1909-1922. https://doi.org/10.1038/s41380-025-03341-1
- Petrova K. Novel psychedelic compound shows rapid antidepressant effects without addictive traits. PsyPost. May 6, 2026. https://www.psypost.org/novel-psychedelic-compound-shows-rapid-antidepressant-effects-without-addictive/
Explore more at https://www.interventionalpsychiatry.org/